SIGNATURE PAGE TO MASTER CLINICAL TRIAL AGREEMENT

Master Clinical Trial Agreement by and between Penterra Pharmaceuticals Corp. and Veridian Health Research Network, Inc. dated as of June 28, 2023

Protocol PPC-4871-III (CLARION — Clinical Assessment of Response with Longitudinal Investigation in ONcology)

IN WITNESS WHEREOF, the undersigned has caused this Master Clinical Trial Agreement to be executed by its duly authorized representative as of the date set forth below.

This signature page is delivered in connection with, and constitutes an integral part of, that certain Master Clinical Trial Agreement (the "Agreement"), entered into by and between Penterra Pharmaceuticals Corp., a corporation organized and existing under the laws of the State of Delaware ("Sponsor"), and Veridian Health Research Network, Inc., a corporation organized and existing under the laws of the State of Delaware ("Site Network"), together with all Exhibits A through K and Schedule 1 attached thereto and incorporated therein by reference, each as may be amended, supplemented, or otherwise modified from time to time in accordance with the terms of the Agreement.

By affixing the signature below, the undersigned hereby represents and warrants that he is a duly authorized representative of Sponsor and has been fully empowered to execute and deliver this Agreement on behalf of Sponsor, and that Sponsor has taken all corporate action necessary to authorize the execution, delivery, and performance of this Agreement and the transactions contemplated hereby.

SPONSOR:

PENTERRA PHARMACEUTICALS CORP.

A corporation organized and existing under the laws of the State of Delaware

PENTERRA PHARMACEUTICALS CORP.

By: ________

Name: Nathaniel Briggs, Esq.

Title: Vice President and General Counsel

Date of Execution: June 28, 2023

Principal Place of Business: 200 Biopharma Boulevard, Suite 1400 Princeton, New Jersey 08540

Attestation. The signature of Nathaniel Briggs, Esq., Vice President and General Counsel, appearing above is hereby attested as duly authorized pursuant to resolutions duly adopted by the Board of Directors of Penterra Pharmaceuticals Corp. at a meeting duly convened and held on May 15, 2023, at which a quorum was present and acting throughout, authorizing the execution and delivery of this Master Clinical Trial Agreement and the performance of all obligations contemplated hereunder. A true, correct, and complete copy of the Secretary's Certificate of Penterra Pharmaceuticals Corp., certifying (i) the adoption of such board resolutions, (ii) the incumbency of Nathaniel Briggs, Esq. as Vice President and General Counsel of Penterra Pharmaceuticals Corp., and (iii) his authority to act as an authorized signatory on behalf of Penterra Pharmaceuticals Corp. with respect to this Agreement and all ancillary documents, instruments, and agreements executed in connection herewith, has been delivered to Site Network concurrently with the delivery of this signature page.

Agreement Identification Details

Counterpart and Related Signature Pages

This signature page constitutes the signature page of Penterra Pharmaceuticals Corp. to the execution version of the Master Clinical Trial Agreement dated as of June 28, 2023, and is to be read and construed in conjunction with the counterpart signature pages executed by:

(a) Veridian Health Research Network, Inc. (Site Network), executed by Dr. Franklin Osei, President and Chief Executive Officer; and

(b) Graystone University Medical Center (Lead Participating Site Institution), executed by Dr. William Corwin, President,

each of which counterpart signature pages has been delivered concurrently herewith or will be delivered promptly following the date hereof.

Pursuant to Section 22.4 of the Agreement, this Agreement may be executed in one or more counterparts, including by means of facsimile or portable document format (.pdf) transmission, each of which when so executed and delivered shall be deemed an original, and all of which counterparts, taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission or by electronic mail in portable document format (.pdf) shall be as effective as delivery of a manually executed counterpart of this Agreement.

CONFIDENTIAL — This signature page and the Agreement to which it relates contain confidential and proprietary information of Penterra Pharmaceuticals Corp. and Veridian Health Research Network, Inc. Any unauthorized review, use, disclosure, or distribution is strictly prohibited. If you are not the intended recipient, please contact Calderwood & Harkness LLP at (212) 555-0199, ref. Matter No. 1018-00004, and destroy all copies of this document.

[Remainder of page intentionally left blank]

Field	Detail
Agreement Title	Master Clinical Trial Agreement
Sponsor	Penterra Pharmaceuticals Corp.
Site Network	Veridian Health Research Network, Inc.
Date of Agreement	June 28, 2023
Protocol	PPC-4871-III (CLARION — Clinical Assessment of Response with Longitudinal Investigation in ONcology)
ClinicalTrials.gov Identifier	NCT05928174
IND Number	IND 157823
Outside Counsel Matter Number	Calderwood & Harkness LLP — 1018-00004
Total Deal Value	$80,000,000
Governing Law	State of New York

SIGNATURE PAGE TO MASTER CLINICAL TRIAL AGREEMENT
Master Clinical Trial Agreement by and between Penterra Pharmaceuticals Corp. and Veridian Health Research Network, Inc. dated as of June 28, 2023
Protocol PPC-4871-III (CLARION — Clinical Assessment of Response with Longitudinal Investigation in ONcology)
IN WITNESS WHEREOF, the undersigned has caused this Master Clinical Trial Agreement to be executed by its duly authorized representative as of the date set forth below.
This signature page is delivered in connection with, and constitutes an integral part of, that certain Master Clinical Trial Agreement (the "Agreement"), entered into by and between Penterra Pharmaceuticals Corp., a corporation organized and existing under the laws of the State of Delaware ("Sponsor"), and Veridian Health Research Network, Inc., a corporation organized and existing under the laws of the State of Delaware ("Site Network"), together with all Exhibits A through K and Schedule 1 attached thereto and incorporated therein by reference, each as may be amended, supplemented, or otherwise modified from time to time in accordance with the terms of the Agreement.
By affixing the signature below, the undersigned hereby represents and warrants that he is a duly authorized representative of Sponsor and has been fully empowered to execute and deliver this Agreement on behalf of Sponsor, and that Sponsor has taken all corporate action necessary to authorize the execution, delivery, and performance of this Agreement and the transactions contemplated hereby.
SPONSOR:
PENTERRA PHARMACEUTICALS CORP.
A corporation organized and existing under the laws of the State of Delaware
PENTERRA PHARMACEUTICALS CORP.
By: ________
Name: Nathaniel Briggs, Esq.
Title: Vice President and General Counsel
Date of Execution: June 28, 2023
Principal Place of Business: 200 Biopharma Boulevard, Suite 1400 Princeton, New Jersey 08540
Attestation. The signature of Nathaniel Briggs, Esq., Vice President and General Counsel, appearing above is hereby attested as duly authorized pursuant to resolutions duly adopted by the Board of Directors of Penterra Pharmaceuticals Corp. at a meeting duly convened and held on May 15, 2023, at which a quorum was present and acting throughout, authorizing the execution and delivery of this Master Clinical Trial Agreement and the performance of all obligations contemplated hereunder. A true, correct, and complete copy of the Secretary's Certificate of Penterra Pharmaceuticals Corp., certifying (i) the adoption of such board resolutions, (ii) the incumbency of Nathaniel Briggs, Esq. as Vice President and General Counsel of Penterra Pharmaceuticals Corp., and (iii) his authority to act as an authorized signatory on behalf of Penterra Pharmaceuticals Corp. with respect to this Agreement and all ancillary documents, instruments, and agreements executed in connection herewith, has been delivered to Site Network concurrently with the delivery of this signature page.
Agreement Identification Details
Counterpart and Related Signature Pages
This signature page constitutes the signature page of Penterra Pharmaceuticals Corp. to the execution version of the Master Clinical Trial Agreement dated as of June 28, 2023, and is to be read and construed in conjunction with the counterpart signature pages executed by:
(a) Veridian Health Research Network, Inc. (Site Network), executed by Dr. Franklin Osei, President and Chief Executive Officer; and
(b) Graystone University Medical Center (Lead Participating Site Institution), executed by Dr. William Corwin, President,
each of which counterpart signature pages has been delivered concurrently herewith or will be delivered promptly following the date hereof.
Pursuant to Section 22.4 of the Agreement, this Agreement may be executed in one or more counterparts, including by means of facsimile or portable document format (.pdf) transmission, each of which when so executed and delivered shall be deemed an original, and all of which counterparts, taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission or by electronic mail in portable document format (.pdf) shall be as effective as delivery of a manually executed counterpart of this Agreement.
CONFIDENTIAL — This signature page and the Agreement to which it relates contain confidential and proprietary information of Penterra Pharmaceuticals Corp. and Veridian Health Research Network, Inc. Any unauthorized review, use, disclosure, or distribution is strictly prohibited. If you are not the intended recipient, please contact Calderwood & Harkness LLP at (212) 555-0199, ref. Matter No. 1018-00004, and destroy all copies of this document.
[Remainder of page intentionally left blank]
Field | Detail
Agreement Title | Master Clinical Trial Agreement
Sponsor | Penterra Pharmaceuticals Corp.
Site Network | Veridian Health Research Network, Inc.
Date of Agreement | June 28, 2023
Protocol | PPC-4871-III (CLARION — Clinical Assessment of Response with Longitudinal Investigation in ONcology)
ClinicalTrials.gov Identifier | NCT05928174
IND Number | IND 157823
Outside Counsel Matter Number | Calderwood & Harkness LLP — 1018-00004
Total Deal Value | $80,000,000
Governing Law | State of New York

SIGNATURE PAGE TO MASTER CLINICAL TRIAL AGREEMENT

SPONSOR:

PENTERRA PHARMACEUTICALS CORP.

PENTERRA PHARMACEUTICALS CORP.

Record

Parties

Dates

Amounts